Fulcrum Therapeutics (FULC) Non-Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Non-Current Assets data on file, last reported at $8.1 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $8.1 million, down 19.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.4 million (down 23.74% YoY), and the FY2025 annual result was $8.8 million, down 18.44% from the prior year.
• Non-Current Assets fell to $8.1 million in Q1 2026 per FULC's latest filing, from $8.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $21.0 million in Q2 2022 and troughed at $8.1 million in Q1 2026.
• A 5-year average of $14.4 million and a median of $14.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 124.02% in 2022, then sank 32.25% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $19.2 million in 2022, then retreated by 19.15% to $15.5 million in 2023, then slumped by 30.33% to $10.8 million in 2024, then retreated by 18.44% to $8.8 million in 2025, then decreased by 7.99% to $8.1 million in 2026.
• Business Quant data shows FULC's Non-Current Assets at $8.1 million in Q1 2026, $8.8 million in Q4 2025, and $9.0 million in Q3 2025.